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C-type lectins are a diverse family of proteins which recognize a wide range of ligands. This review
focuses on the Dectin-2 family of C-type lectins that includes Dectin-2, BDCA-2, DCIR, DCAR, Clecsf8
and Mincle whose genes are clustered in the telomeric region of the NK-gene cluster on mouse chromo-
some 6 and human chromosome 12. These type II receptors are expressed on myeloid and non-myeloid
cells and contain a single extracellular carbohydrate recognition domain and have diverse functions in
both immunity and homeostasis. DCIR is the only member of the family which contains a cytoplasmic
signalling motif and has been shown to act as an inhibitory receptor, while BDCA-2, Dectin-2, DCAR
and Mincle all associate with FcRc chain to induce cellular activation, including phagocytosis and cyto-
kine production. Dectin-2 and Mincle have been shown to act as pattern recognition receptors for fungi,
while DCIR acts as an attachment factor for HIV. In addition to pathogen recognition, DCIR has been
shown to be pivotal in preventing autoimmune disease by controlling dendritic cell proliferation,
whereas Mincle recognizes a nuclear protein released by necrotic cells. Here we review each of these
receptors in detail describing their expression, ligand recognition, signalling and known physiological
functions.
 2009 Elsevier Ltd. Open access under CC BY license.1. Introduction
To execute both immune and non-immune functions, leuko-
cytes interact with various cell types, both directly and through
soluble factors. These interactions are controlled by an array of
receptors which are essential for diverse but speciﬁc functions,
including leukocyte development, differentiation, migration, pro-
liferation, maturation and survival, as well as for discrimination
between non-threatening self-antigens and foreign matter. Many
receptors also have the ability to distinguish between healthy
and abnormal self, such as virally infected, tumorous or apopto-
tic/necrotic cells. The ligands for these receptors vary greatly, rang-
ing from endogenous molecules to speciﬁc molecular structures
found in microbes called pathogen associated molecular patterns
(PAMPs) [1]. PAMPs are not found in the host, enabling discrimina-
tion between self and non-self and are essential for the microbe’s
survival, limiting the possibility of escape through mutation.
Although termed ‘pathogen associated’, it is important to note that
PAMPs are also found in nonpathogenic microbes [2]. The recep-
tors recognizing these structures are germ-lined encoded and have
been termed pattern recognition receptors (PRRs) [3].n of Immunity and Infection,
st, University of Aberdeen,
ax: +44 (0)1224 555766.
rown).
Y license.A family of receptors of particular interest are the C-type lec-
tins; a diverse group of proteins which were originally deﬁned
by their ability to recognize carbohydrate structures [4]. C-type
lectins execute both immune and non-immune functions. While
some recognize endogenous ligands to facilitate adhesion between
cells, adhesion of cells to extracellular matrix and other non-enzy-
matic functions, others may act as PRRs.
C-type lectins consist of a distinct protein fold, termed the car-
bohydrate recognition domain (CRD), which is generated through
disulphide bridges between conserved cysteine residues. This fam-
ily has been divided into 17 groups based on the organization of
their CRDs, and can be functionally deﬁned as either classical or
non-classical [5,6]. Classical C-type lectins contain conserved resi-
dues in their CRDs which are responsible for forming Ca2+ binding
sites and also generally contain conserved motifs which typically
bind carbohydrate ligands, such as the EPN amino acid triplet
which binds mannose-type carbohydrates or the QPD triplet which
binds galactose-type carbohydrates. Non-classical C-type lectins or
lectin-like receptors generally do not contain these residues and
are more likely to, but do not necessarily, bind non-carbohydrate
ligands, such as those encoded by the Natural killer-gene complex
(NKC) which control cellular activation by recognition of MHC class
I molecules [5,7].
Upon ligand recognition, C-type lectins can induce a variety of
cellular responses, and can be further functionally divided into
those that inhibit or those that induce cellular activation. In gen-
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tyrosine-based inhibitory motif (ITIM) in their cytoplasmic do-
mains, while activation receptors either contain an immunorecep-
tor tyrosine-based activation motif (ITAM), or associate with
signalling adaptor molecules such as DAP12, DAP10 or FcRc chain.
In myeloid cells, signalling through an ITAM-bearing receptor re-
sults in activation of Src homology 2 (SH2) domain-containing pro-
tein tyrosine kinases (e.g. Syk) which leads to various cellular
outcomes, such as induction of phagocytosis, the respiratory burst
and the production of cytokines and chemokines [8]. Upon phos-
phorylation of ITIM-bearing receptors, SH2-containing phospha-
tases are recruited which dephosphorylate the tyrosines of
activation kinases, thereby downmodulating cellular activation
[9]. Recently however, it has become apparent that this dichotomy
is not always clear cut, as some ITAMs have been shown to mediate
cellular inhibition while ITIMs induced activation [10,11]. None the
less, it is generally accepted that pair(s) of immunoreceptors on
cells maintain the balance between cellular activation and inhibi-
tion and defects in this control have often been associated with
excessive inﬂammation, autoreactivity and disease [12–14].
To date, particular interest has been paid to the C-type lectins
encoded in the NKC, situated on mouse chromosome 6 and the
syntenic region on human chromosome 12p13 [7]. Although many
receptors of the NKC are expressed primarily by NK and T cells, a
growing number have been found to be expressed on myeloid cells
[15]. In contrast to the NK and T cell speciﬁc receptors which func-
tion mostly in detection of tumorous or virally infected cells, lar-
gely by means of MHC class I recognition, the myeloid expressed
receptors seem to have a more diverse repertoire of ligands and
cellular functions, including pathogen recognition and mainte-
nance of homeostasis [7]. The Dectin-1 cluster of receptors is one
such example, which includes Dectin-1, lectin-like oxidized low-
density lipoprotein receptor-1 (LOX-1), C-type lectin-like recep-
tor-1 (CLEC-1), CLEC-2, CLEC12B, CLEC9A and myeloid inhibitory
C-type lectin-like receptor (MICL) and form part of the Group V
C-type lectin-like receptors [16]. These receptors have similar
structural features but recognize diverse endogenous and exoge-
nous ligands. CLEC-2 for example, recognizes the endogenous li-
gand podoplanin, as well as the snake venom toxin rhodocytin
[17–20]. Dectin-1 has been shown to speciﬁcally recognize fungal
(1,3)-linked b-glucans, while CLEC9A recognizes a ligand in necro-
tic cells [21,22]. Another cluster of receptors gaining interest is the
Dectin-2 family of C-type lectins. These receptors are clustered in
the telomeric region of the NKC, in close proximity to the Dectin-
1 family (Fig. 1) and also appear to have diverse functions in both
immunity and homeostasis.2. The Dectin-2 family of C-type lectins: an overview
The Dectin-2 cluster is comprised of Dectin-2, DCIR, DCAR,
BDCA-2, Mincle and Clecsf8, which are members of the Group IIBD
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Fig. 1. The Dectin-2 family genes form a cluster in the telomeric region of the NKC. The D
form a cluster (red square) in the telomeric region of the NKC, close to the Dectin-1 cluC-type lectin family. They are all encoded by six exons and share
a common structure, consisting of a single extracellular CRD, a
stalk region of varying length, a transmembrane region, and a cyto-
plasmic domain which is generally short (with the exception of
DCIR; Fig. 2). The receptors demonstrate type II transmembrane
topology, where the C-terminal encodes the extracellular region
of the protein and the N-terminal encodes the intracellular region.
The presence of conserved residues typically associated with Ca2+
binding categorises these receptors as classical C-type lectins,
and indeed Dectin-2 and Mincle have been shown to bind sugar
ligands, but there are also non-carbohydrate ligands such as
SAP130, an endogenous protein recognized by Mincle. Members
of this family generally lack consensus signalling motifs in their
cytoplasmic domains, however the presence of a positively charged
residue in the transmembrane region of the receptors aids the
association with ITAM-containing adaptor molecules, such as the
FcRc chain. DCIR is the only member of this family to contain a sig-
nalling motif (ITIM) and has been postulated to function as a paired
immunoreceptor with other members of this cluster [23].
The Dectin-2 cluster has revealed exciting new insights into C-
type lectin functions, although the physiological roles of most
members remain poorly deﬁned. The elucidated functions include
fungal and viral pathogen recognition, sensing of necrotic cell
death, facilitation of antigen cross-presentation, as well as control
of the development of autoimmunity. In this review we will dis-
cuss each member of the family individually, describing expres-
sion, ligand recognition, signalling and known physiological
functions.
2.1. Blood dendritic cell anitgen 2 (BDCA-2)
BDCA-2 is most well known as a speciﬁc marker for human
plasmacytoid DCs (pDCs). BDCA-2 was originally identiﬁed by a
monoclonal antibody panel raised against CD4+ blood DCs, and
found to be exclusively expressed on CD11c-CD123high pDCs with
expression being lost upon maturation with IL-3 [24]. BDCA-2
transcript was weakly detected in tonsils, bone marrow, pancreas,
testis, ovary, lymph nodes and peripheral blood leukocytes [25,26].
In tonsils, BDCA-2 protein expression was restricted to CD123+
pDCs found in the T cell-rich areas but not in the germinal centres
[25]. Similarly, in immunohistochemical analysis of testis obtained
from patients with testicular cancer, neoplastic and normal epithe-
lium were negative for BDCA-2 staining while CD123+ pDCs were
found to associate with lymphoid aggregates in tumours [25]. This
suggested that expression of BDCA-2 in tissues was linked to inﬁl-
trating pDCs and it is now widely accepted that BDCA-2 expression
is in fact restricted to pDCs. At least ﬁve truncated BDCA-2 mRNA
species have been detected, which if translated would give rise to
variants lacking different domains, including three variants lacking
the transmembrane domain, which may represent soluble forms of
the receptor [25,26]. To date, the murine homologue(s) of BDCA-2
remain unknown.LO
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Fig. 2. Cartoon representation of the Dectin-2 family of C-type lectins. Members of the Dectin-2 family of C-type lectins are type II proteins with a single C-terminal
extracellular carbohydrate recognition domain (CRD), a stalk region, a transmembrane region (TM), and a cytoplasmic domain (cyto). DCIR contains an immunoreceptor
tyrosine-based signalling motif (ITIM) in its cytoplasmic domain, while BDCA-2, DCAR, Dectin-2 and Mincle associate with FcRc chain which contains an ITAM. It is not yet
known whether Clecsf8 associates with an adaptor molecule (?). The star represents the region responsible for association with the adaptor. R, arginine.
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receptor have not yet been identiﬁed. Furthermore, the ligands
may not be mannose-based, as BDCA-2 from cell lysates was
shown not to recognize these carbohydrates [26,27]. In the absence
of a ligand, an anti-BDCA-2 monoclonal antibody was used to
cross-link the receptor on pDCs and transfected U937 cells, result-
ing in src-family kinase dependent Ca2+ inﬂux and intracellular
protein phosphorylation [25,28]. Immunoprecipitation and expres-
sion studies in transfected 293T and Jurkat cells and freshly iso-
lated pDCs, revealed that BDCA-2 couples with FcRc chain
[28,29]. Indeed, in Jurkat cells co-transfected with BDCA-2 and
FcRc chain, stimulation of BDCA-2 induced intracellular protein
phosphorylation and Ca2+ inﬂux which was not possible when
BDCA-2 was expressed alone [25,28]. The association with FcRc
chain has been shown to take place through the transmembrane
domain and this interaction is unusual as BDCA-2 does not contain
a positively charged residue in this region [29].
Signalling through BDCA-2 is dependent on the ITAM motif in
the FcRc chain and downstream pathways involve Syk, Src homol-
ogy 2 domain-containing leukocyte protein of 65 kDa (Slp65),
Vav1, phospholipase C-gamma (PLCc2) and Erk1/2 [28,29]. This
cascade in primary human pDCs resembles signalling via the B cell
receptor in B cells. BDCA-2 signalling does not however, lead to
activation of the NF-jB pathway. In fact, cross-linking of BDCA-2
on pDCs actually decreased activation of the NF-jB pathway fol-
lowing stimulation with TNF-a [29]. Interestingly, amongst the
proteins phosphorylated after BDCA-2 triggering, Röck et al. iden-
tiﬁed those involved in cytoskeletal rearrangement, including
actin, tubulin and clatherin heavy chain [29]. This, and the fact that
BDCA-2 contains an EEE (late endosomal sorting) motif in its cyto-
plasmic tail, may indicate targeting of the receptor to late endo-
somal compartments. Accordingly, when antibody was used to
cross-link BDCA-2 on the surface of pDCs, BDCA-2-antibody com-
plexes were internalised and efﬁciently presented to T cells, indi-
cating a possible role for BDCA-2 in antigen capture and
presentation [24,25].
Following BDCA-2 cross-linking on pDCs, the cells’ ability to
produce IFN-a, IFN-b and IL-6 was found to be suppressed in
response to CpG-DNA but the production of other cytokines,
including IL-12p40, IL-12p70, IL-4 and IL-10, remained unaffected
[25,28,29]. Additionally, when BDCA-2 was cross-linked on CpG-DNA stimulated pDCs, these pDCs had decreased ability to stimu-
late CD4+ T cells to proliferate and produce IFN-c [30]. These stim-
ulated CD4 + T cells also showed enhanced expression of CCR5 and
decreased expression of CCR4, which are markers of Th2 and Th1
differentiation respectively [30]. These results indicate that
BDCA-2 may function in skewing the immune system away from
a proinﬂammatory Th1 response, by decreasing IFN production, to-
wards a Th2 response, characterized by increased CCR5+ T cells. As
pDCs have been shown to play a role in the pathogenesis of sys-
temic lupus erythematosis, by being the main producers of in-
creased levels of IFN-a/b associated with this autoimmune
disease, BDCA-2 has been proposed to be a therapeutic target for
treatment of this disease [31].
2.2. Dendritic cell immunoactivating receptor (DCAR)
There is only one publication on DCAR, a molecule identiﬁed by
a cDNA homology search with the DCIR CRD [32]. DCAR transcripts
were strongly detected in lung, spleen and bone-marrow DCs,
weakly in skin and lymph node and not at all in bone-marrow
NK cells [32]. The cytoplasmic domain of DCAR is characteristically
short and lacks a deﬁned signalling motif but the receptor was
found to associate with the FcRc chain, partly by association with
an arginine residue in the transmembrane region of DCAR. In A20
cells co-transfected with the FcRc chain, cross-linking a chimeric
receptor consisting of the extracellular region of FccRIIB coupled
to the transmembrane and intracellular domains of DCAR, resulted
in tyrosine phosphorylation of intracellular proteins and Ca2+
mobilization. When the tyrosine of the FcRc chain was mutated
to a phenylalanine, the Ca2+ mobilization was no longer observed,
demonstrating that signalling from DCAR takes place via the ITAM
motif of the adaptor. The FcRc chain is also likely to be required for
surface expression of DCAR, as it enhanced receptor expression in
transduced in 293T cells. Two isoforms of DCAR have been identi-
ﬁed, one of which lacks the stalk region, but the ligands and biolog-
ical functions of these isoforms still remain undeﬁned.
2.3. Dendritic cell immunoreceptor (DCIR)
DCIR was identiﬁed by screening a nucleotide database for mol-
ecules homologous to the Group II C-type lectin hepatic asialogly-
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minal end [33]. DCIR mRNA was found to be highly expressed in
human peripheral blood leukocytes, and at lower levels in lymph
node, spleen, bone marrow and thymus, while mouse DCIR was
found to be expressed at highest levels in spleen and lymph node,
although peripheral blood was not examined [33,34]. A closer look
at protein expression on cells, revealed that DCIR was expressed on
antigen presenting cells such as CD14+ monocytes, CD19+ B cells,
macrophages, neutrophils as well as myeloid and plasmacytoid
DCs (pDCs), but not on CD3+ T cells nor on CD56+ or CD16+NK cells
[33–36]. In vitro, DCIR expression was found to be higher in CD14+
than CD1a+ derived DCs, while monocyte-derived DCs (moDCs)
had high levels of expression throughout differentiation, which
was downregulated upon maturation with LPS or CD40 ligand
[33]. Additionally, DCIR expression on neutrophils was downregu-
lated by TNF-a, IL-1a and LPS stimulation but anti-inﬂammatory
stimuli, including IL-4, IL-10 and IL-13, did not affect expression,
suggesting that DCIR may be downregulated during inﬂammation
[35]. Interestingly, GM-CSF, IL-3, IL-4 and IL-13 stimulation of neu-
trophils resulted in accumulation of a short form of DCIR mRNA,
which encodes a putative non-functional protein which may act
as an antagonist to the full-length receptor [35,37].
DCIR is distinct from other members of this receptor family in
that it possesses a longer cytoplasmic tail which contains a consen-
sus signalling motif and is the ﬁrst reported DC-expressed ITIM-
bearing C-type lectin [33]. The presence of this ITIM motif, and
downregulation of DCIR in proinﬂammatory settings, suggests a
regulatory role for this receptor. The function of the intracellular
domain of DCIR has been studied using B cells transformed with
a chimeric receptor comprising the extracellular domain of FccRIIB
coupled to the intracellular domain of DCIR [34]. Stimulation of the
B cell receptor in these cells resulted in Ca2+ mobilization and
intracellular protein tyrosine phosphorylation and these activities
could be inhibited by co-ligation with the chimeric receptor [34].
This inhibition was completely lost when the tyrosine of the DCIR
ITIM motif was mutated to a phenylalanine [34]. Moreover, immu-
noprecipitations using a phosphorylated peptide covering the DCIR
ITIM demonstrated association with the inhibitory phosphates, Src
homology 2-containing tyrosine phosphatase 1 (SHP-1) and SHP-2
[38]. Accordingly, in pDCs, which are generally considered to in-
duce Th1 polarization in response to viral stimuli, stimulation with
TLR9 ligand resulted in the production of large amounts of IFN-a,
which could be inhibited by cross-linking of DCIR with anti-DCIR
antibodies, similar to BDCA-2 [36]. Cross-linking of DCIR on imma-
ture moDCs stimulated with other TLR ligands including LPS
(TLR4), polyIC (TLR3), zymosan (TLR2 and 4) and R848 (TLR8),
resulted only in the inhibition of the TLR8-mediated responses,
demonstrating some selectivity in DCIR function [39]. Cross-link-
ing DCIR in pDCs and moDCs also resulted in internalization of
the receptor into intracellular vesicles in a clatherin-dependent
manner [36,39]. Furthermore, once internalized, DCIR was able to
deliver antigen into the antigen-presentation pathway, resulting
in efﬁcient T cell proliferation [36].
DCIR also plays a role in the capture and transmission of HIV-1
by DCs [40]. Decreasing DCIR surface expression on human IM-
moDCs with small-interfering RNA, or blocking the receptor with
antibodies, signiﬁcantly reduced transfer of HIV-1 virions to autol-
ogous CD4+ T cells [40]. Additionally, Raji-CD4 cells transiently
expressing DCIR were shown to have both increased binding to
HIV-1 and enhanced virus production, following infection, com-
pared to DCIR-negative cells. It has been proposed that DCIR inter-
action with HIV could allow the virus to gain access to
nondegradative endosomal organelles and lead to fusion of viral
and endosomal membranes, allowing productive infection of the
cells [40]. To study association with HIV-1, a DCIR mutant which
lacked the stalk region was created. Although the receptor wasexpressed on the surface of Raji-CD4 cells, it did not increase
attachment or replication of virus particles, indicating a crucial role
for the stalk region of DCIR in HIV-1 interaction, perhaps by
extending the CRD from the cell surface and making it available
for attachment [40].
In addition to acting as a PRR for HIV, DCIR has been shown to
play a role in controlling autoimmune disease [13]. Aged DCIR deﬁ-
cient mice were found to spontaneously develop joint abnormali-
ties, have elevated levels of autoantibodies and show higher
levels of CD11c+ DCs and a proportional expansion of T cell popu-
lations in their lymph nodes [13]. Additionally, in response to col-
lagen-induced arthritis, young DCIR deﬁcient mice were found to
develop a more severe disease than their wild type littermates,
indicating a protective role for DCIR [13]. DCIR deﬁcient mice also
had elevated levels of IL-4, IL-10, IL-17 and IL-23 after type II col-
lagen immunization, consistent with a negative regulatory role
played by the receptor [13]. Additionally, bone-marrow cells from
DCIR deﬁcient mice differentiated into DCs and proliferated more
efﬁciently than wildtype cells, due to an increased responsiveness
to GM-CSF. DCIR therefore appears to be crucial in maintaining
appropriate DC numbers to prevent development of autoimmunity
in mice [13]. When studying DCIR expression in patients with
rheumatoid arthritis, the receptor was found to be abundantly ex-
pressed in synovial biopsies but was not found in those of healthy
controls [41]. In these biopsies, the receptor was expressed on
numerous cell types and surprisingly also on CD56+ NK cells and
CD4+ and CD8+ T cells [41]. DCIR+ T cells in the synovial ﬂuid were
activated, as well as much more abundant, than those found in
peripheral blood [41]. The function of DCIR on T cells in this disease
setting is as of yet undeﬁned. Overall, these observations suggest
DCIR has an essential role in maintaining homeostasis of the im-
mune system by controlling DC expansion and the development
of autoimmune disease.
2.4. Dendritic cell-associated C-type lectin-2 (Dectin-2)
Dectin-2 is the most well characterized member of this receptor
family and was identiﬁed as an over-expressed transcript in a mye-
loid leukaemia mouse model and in macrophages, neutrophils and
pleuripotent myeloid precursors [42]. Although originally pro-
posed to be Langerhans cell speciﬁc, the use of a Dectin-2 speciﬁc
monoclonal antibody has demonstrated that the receptor is
expressed predominantly in tissue macrophages, some DCs and
at a low level on Langerhans cells and peripheral blood monocytes,
where expression levels could be transiently increased upon induc-
tion of inﬂammation [43]. The Dectin-2 promoter was also deﬁned
as a Langerhans cell speciﬁc regulatory element and, while numer-
ous splice forms of Dectin-2 mRNA were shown to be highly
expressed in a Langerhans cell-like skin-derived cell line compared
to other cell lines, these transcript were also found to be abundant
in spleen and thymus [44,45].
Dectin-2 was predicted to have mannose binding activity due to
the presence of an EPN motif in the CRD [42]. Use of a soluble form
of the CRD of Dectin-2 as a probe, revealed that the receptor could
recognize zymosan and numerous pathogens including Candida
albicans, Saccharomyces cerevisiae, Mycobacterium tuberculosis,
Microsporum audounii, Trichophyton rubrum Paracoccoides brasilien-
sis, Histoplasma capsulatum and capsule-deﬁcient Cryptococcus neo-
formans. Although the level of binding to these pathogens differed
greatly, binding could always be inhibited by chelation of Ca2+ or
competition with mannose [46,47]. Additionally, a glycan micro-
array showed that the receptor had speciﬁcity for high-mannose
structures [46].
Interestingly, Dectin-2 may also have an endogenous ligand on
CD4+CD25+ T cells and interaction of the two molecules may
mediate UV-induced immunosuppression [48]. More speciﬁcally,
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duced suppression of contact hypersensitivity, supposedly by
inhibiting the interaction of endogenous Dectin-2 with its puta-
tive ligand on regulatory T cells [48]. Indeed, UV-B irradiation
was shown to increase Dectin-2 expression in Langerhans cells
of the skin at both mRNA and protein levels [49]. It is possible
that Dectin-2 recognises an endogenous ligand that is not a car-
bohydrate, perhaps via an alternative binding site to that which
recognises fungi, as has been reported for other C-type lectins,
such as Dectin-1 [50].
Delivering antigens directly to DCs has the potential to increase
the efﬁcacy of vaccination and Dectin-2 has been proposed to act
as a target for this delivery [51]. Carter et al. showed that even
though Dectin-2 is expressed at low levels on DCs, anti-Dectin-2
monoclonal antibodies conjugated to ovalbumin were capable of
targeting this model antigen to the cells and increasing presenta-
tion to CD8+ T cells [51]. Induction of a CD8+ T cell response could
even be achieved with an antigen dose which was too low to
induce a response when administered alone [51].
As mentioned, Dectin-2 has been identiﬁed as a PRR for fungi
but the receptor appears to exhibit preferential recognition of
hyphal over conidial forms [46,47]. Binding of C. albicans hyphae
by RAW cells transduced with Dectin-2 resulted in tyrosine phos-
phorylation of intracellular proteins [47]. Cross-linking the recep-
tor with a speciﬁc antibody demonstrated similar protein
phosphorylation levels, as well as internalization of the receptor
into endosomes, activation of transcription factor NF-jB and pro-
duction of TNF-a and IL-1 receptor antagonist, indicating that the
receptor is able to transduce intracellular signals [47]. Dectin-2
has the characteristic short cytoplasmic domain which lacks
known signalling motifs and associates with FcRc chain to trans-
duce these signals [47]. Interestingly, it was not the positively
charged arginine in the transmembrane region which was respon-
sible for association with FcRc chain, as has been shown for other
receptors, but rather a short region of the cytoplasmic domain
proximal to the transmembrane region [47].
Most recently, Dectin-2 has been shown to play a role in
response to allergens [52]. Dectin-2 on bone-marrow-derived
DCs (BMDCs) was able to bind to extracts from house dust mite
(Dermatophagoides farinae and Dermatophagoides pteronyssinus)
and Aspergillus fumigatus in a mannose-dependent manner [52].
Stimulation of mast cells co-expressing Dectin-2 and FcRc chain
with these extracts resulted in production of cysteinyl leukotri-
enes, proinﬂammatory lipid mediators which are not produced
by untransfected cells [52]. Additionally, in primary BMDCs, signal-
ling by Dectin-2 to produce cysteinyl leukotriene in response to the
extracts was dependent on Syk kinase and FcRc chain, and lentiv-
iral knockdown of the receptor signiﬁcantly reduced this activity
[52].
Most of the work studying Dectin-2 has been performed in the
mouse, however two reports describe identiﬁcation and character-
ization of human Dectin-2 (hDectin-2) [53,54]. In tissues, hDectin-
2 transcripts were detected in lung, spleen, lymph node, leuko-
cytes, bone marrow and tonsils, but unlike mouse, Dectin-2 was
not expressed in the human thymus. In peripheral blood cells,
hDectin-2 transcripts were shown to be preferentially expressed
in plasmacytoid, rather than myeloid, DCs and constitutively ex-
pressed in CD14+ monocytes and B cells, and could be induced in
CD4+ T cells upon activation with Con A [53,54]. Indeed, similar
to mouse Dectin-2, hDectin-2 appears to be upregulated in inﬂam-
matory settings, as gene expression in CD14+ monocytes could be
upregulated by treatment with GM-CSF, TGF-b1 and TNF-a and
downregulated with the addition of IL-4 and IL-10 [54]. In CD8+
T cells however, transcripts were detectable in inactive cells but
decreased upon activation with phytohemagglutinin [54]. hDec-
tin-2 was also expressed on Langerhans cells, however, while thisexpression was upregulated upon UV-B radiation in mice, it was
downregulated in human cells [54]. These contradicting ﬁndings
may be due to the fact that CD14+ monocytes were used as a sur-
rogate model for epidermal Langerhans cells in the human exper-
iment [49,54].
Interestingly a truncated isoform of hDectin-2 has been identi-
ﬁed which lacks part of the intracellular domain and most of the
transmembrane domain of the receptor [54]. The lack of trans-
membrane region has been proposed to encode a secreted protein
which may act as an antagonist to full-length Dectin-2 [54]. Alter-
natively, this truncated version may act in a similar manner to hu-
man Dectin-1 isoform E, which also lacks a transmembrane region.
This isoform was retained intracellularly where it interacted with
Ran-binding protein, a molecule which is presumed to act as a scaf-
fold protein to coordinate signals from cell surface receptors with
intracellular signalling pathways [55].
2.5. Clecsf8
Murine Clecsf8 was ﬁrst identiﬁed through a differential dis-
play PCR screen of numerous cell lines for macrophage-speciﬁc
genes [56]. Northern blot analysis of mouse tissues revealed that
Clecsf8 transcripts were predominantly expressed in resident per-
itoneal macrophages and at lower levels in bone marrow, spleen,
lung and lymph nodes, however peripheral blood was not exam-
ined [56]. The Clecsf8 open reading frame encodes a 219 amino
acid protein with typical Group II characteristics, including a
short cytoplasmic domain with no signalling motif, and a CRD
with conserved Ca2+ association residues [56]. The CRD however,
does not contain the conserved EPN or QPD amino acid triplets
associated with carbohydrate recognition and the transmembrane
region lacks charged residues normally involved in association
with an adaptor molecule. Cross-linking of Clecsf8 on 293T cells
transiently expressing the receptor resulted in internalization of
the molecule, indicating a potential role for the receptor in anti-
gen uptake [57].
The human orthologue of mouse Clecsf8 was also found to be
expressed in a monocyte/macrophage restricted manner, and
interestingly, freshly isolated peripheral blood monocytes were
found to have higher mRNA levels than cultured or buffy-coat iso-
lated monocytes [57]. The expression of this receptor could be
upregulated on these cells by stimulation with IL-6, IL-10, TNF-a
or IFN-c, but was downreglated with LPS [57]. Clecsf8 transcripts
were detected in peritoneal macrophages from a patient suffering
from Pseudomonas aeruginosa induced peritonitis as well as in
synovial ﬂuid macrophages isolated from a patient with rheuma-
toid arthritis, but not from a patient with gout [57]. In gout, mac-
rophages have been implicated in the generation of anti-
inﬂammatory rather than proinﬂammatory cytokines [58].
Although no ligand or biological function has as yet been described
for Clecsf8, the receptor has been shown to be upregulated at the
transcript level in a number of disease settings, including TNF-a
over-expressing myocarditis and M. tuberculosis infection [59,60].
Overall these preliminary indications suggest that Clecsf8 could
be upregulated in proinﬂammatory settings, as has been described
for Mincle and Dectin-2.
Very little is known about the true function of the receptor
although a Clecsf8-deﬁcient mouse has been generated, offering
an exciting reagent for future studies. This mouse has been gener-
ated and phenotypically characterized by The Consortium for
Functional Glycomics (www.functionalglycomics.org/glycomics/
publicdata/phenotyping.jsp). Clecsf8 deﬁciency suggested im-
paired T cell and B cell proliferation, following stimulation of the
antigen receptors, as well as a possible increase in mature recircu-
lating B cells found in the bone marrow, but none of these ﬁndings
were signiﬁcantly different to wildtype mice.
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The Mincle gene was originally identiﬁed as a transcriptional
target of nuclear factor (NF-) IL-6 in peritoneal macrophages
[61]. This transcription factor has low transcriptional activity un-
less activated by inﬂammatory stimuli and accordingly, Mincle
gene expression can be induced in peritoneal macrophages upon
stimulation with LPS, IFN-c, IL-6 or TNF-a [61]. Mincle transcript
was also detected in RAW macrophages and could be upregulated
upon LPS stimulation, as well as LPS stimulated M1 myeloblastic
leukaemia cells, but the receptor was not expressed in other cell
lines including myeloma, mature B cells, NK cells, EL4 thymoma
or NIH3T3 ﬁbroblasts [61].
Like Dectin-2, Mincle was able to recognize fungi and induce
inﬂammatory signals. Initially, microarray analysis of Mincle
expression suggested that the gene was upregulated in bone-mar-
row-derived macrophages exposed to Candida albicans yeast and a
soluble Mincle protein was subsequently found to bind to C. albi-
cans and Sacccharomyces cerevisiae in an ELISA-based assay [62].
In this study, both human (in transduced cells) and mouse (in wild-
type cells) Mincle were examined and it was found that although
Mincle was not a phagocytic receptor for C. albicans, it was able
to mediate inﬂammatory responses to the yeast. In transfected
RAW cells, Mincle recognition of C. albicans induced the production
of TNF-a, which could be partially inhibited by blocking with an
anti-Mincle antibody and bone-marrow-derived macrophages
from Mincle knockout mice produced less TNF-a than wildtype
cells [62]. This study also used Mincle knockout mice to study sys-
temic C. albicans infection and found that Mincle knockout mice
had signiﬁcantly higher fungal burdens in the kidneys than wild-
type mice, demonstrating that the receptor was involved in patho-
gen clearance [62]. Interestingly, mice deﬁcient in the NF-IL-6
transcription factor, which controls Mincle expression, are alsoI
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Fig. 3. Mincle is a detector of necrotic cell death. Necrotic cell death induced by injury, su
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Mincle. Nat Immunol 2008;9:1099–1100).susceptible to infection with Candida [63]. However, the suscepti-
bility of knockout animals to a lethal dose of fungus has not been
investigated.
Most recently however, another group were not able to demon-
strate the recognition of Candida by Mincle. Using a non-myeloid
cell-based NFAT-GFP reporter system to screen 50 different fungal
species, including Candida spp. and S. cerevisiae, Mincle was found
to recognize only Malassezia species [64]. It is however important
to note that the Candida spp. screened in this system were not
the same strains used in the study described above. As Mincle con-
tains an EPN motif, it was postulated that it speciﬁcally recognises
mannose on the fungal surface and accordingly, mutation of the
EPN into QPD resulted in loss of recognition [64]. Additionally, a
carbohydrate microarray showed soluble Mincle bound a multiva-
lent form of a-mannose in a Ca2+ dependent manner [64]. Upon
stimulation with Malassezia, bone-marrow-derived macrophages
from wildtype mice showed increased Mincle expression and pro-
duction of MIP-2, TNF-a, KC and IL-10, which was signiﬁcantly
reduced in Mincle knockout cells [64]. This indicates a role for Min-
cle in eliciting an immune response to Malassezia by macrophages.
Additionally, intraperitoneal injection of Malassezia resulted in
impaired IL-6 and TNF-a production as well as neutrophil inﬁltra-
tion in the Mincle deﬁcient mice, compared to their wildtype litter-
mates [64].
Similar to BDCA-2, DCAR and Dectin-2, Mincle has been shown
to associate with FcRc chain in transduced HEK293T cells and
mouse peritoneal macrophages [65]. This interaction was found
to take place via the positively charged arginine in the transmem-
brane region of Mincle and was crucial for signalling through the
receptor [65]. Indeed, cross-linking of Mincle on thioglycollate
elicited peritoneal macrophages with an anti-Mincle antibody re-
sulted in the production of TNF-a, MIP-2, KC and IL-6, and this
activity was lost in FcRc deﬁcient cells [65]. This signalling wasNeutrophil recruitment
ch as radiation, results in the release of preformed nuclear proteins such as SAP130.
ia FcRc chain, in a Syk and CARD9 dependant pathway. This induces the production
neutrophils to the site of necrosis. (Adapted from: Brown GD. Sensing necrosis with
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(CARD9) pathway and to be independent of MyD88 signalling,
suggesting that Mincle does not require cooperation with TLRs
to induce cytokine production [65]. While FcRc chain was not
essential for cell surface expression of Mincle, LPS stimulation
was found to induce less Mincle expression on the surface of FcRc
deﬁcient macrophages than wildtype cells, indicating that the
adaptor was involved, at least partly, in surface expression of
the receptor [65].
In addition to fungi, Yamasaki et al. have shown that Mincle can
mediate inﬂammatory responses to necrotic cells [65]. In a search
for an endogenous ligand using the NFAT-GFP reporter cell system,
the authors discovered that cellular activation occurred following
prolonged cultured and noticed that this activity correlated with
the presence of dead cells [65]. Mutation of the EPN motif in the
CRD did not abrogate cellular activation in response to dead cells,
nor was binding by a soluble Mincle protein inhibited in the ab-
sence of Ca2+, suggesting that Mincle was recognising a non-carbo-
hydrate endogenous ligand [65]. Immunoprecipitation from dead-
cell lysates identiﬁed spliceosome-associated protein 130
(SAP130), a soluble protein that is localized in the nucleus of living
cells and released during cellular necrosis. Stimulation of macro-
phages or Mincle expressing T cell hybridomas with puriﬁed
SAP130 resulted in production of MIP-2 and IL-2 respectively,
showing that SAP130 is a functional endogenous ligand for Mincle
and that recognition of this protein could act as a signal for exces-
sive cell death [65]. To study the function of Mincle in response to
necrotic cell death in vivo, Yamasaki et al. inhibited Mincle function
with blocking antibodies and found decreased neutrophil recruit-
ment and cytokine production in response to cell death [65]. This
model therefore proposes that Mincle recognises SAP130 released
by necrotic cells which results in cytokine production by macro-
phages and subsequent neutrophil inﬁltration into the damaged
tissue (Fig. 3). Speculatively, this inﬁltration could be either bene-
ﬁcial or detrimental to the host. The neutrophils may aid in clear-
ance of apoptotic cells and promote repair or they may induce
acute inﬂammation with a pathological outcome, such as in auto-
immune diseases. Indeed, the Mincle gene complex has been re-
ported to be associated with rheumatoid arthritis. Further studies
in Mincle deﬁcient mice are needed to understand the role of the
receptor in autoimmunity [13,66,67].3. Concluding remarks
The Dectin-2 family are multifunctional receptors, and have
been shown to be important in both homeostasis and immunity.
Many can act as PRRs and they recognize a range of pathogens,
including fungi and viruses and probably others. Many also recog-
nize endogenous ligands, highlighting the importance of this fam-
ily in homeostasis. Indeed, the Dectin-2 locus has been identiﬁed
as a susceptibility region associated with autoimmune disorders,
including multiple sclerosis, systemic lupus erythematosus, rheu-
matoid arthritis and type I diabetes [68]. DCIR has been shown to
be pivotal in preventing autoimmune arthritis in mice, and it is
possible that Mincle recognition of necrotic cells may also lead to
exacerbated inﬂammation and autoimmunity. With most of the
receptors in the Dectin-2 cluster yet to be fully characterized, these
ﬁrst glimpses of the diverse repertoire of ligands and functions re-
veals an exciting area of future research.
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